Financial Management Professionals Inc. Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Financial Management Professionals Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 11.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,089 shares of the biopharmaceutical company’s stock after buying an additional 2,000 shares during the period. Financial Management Professionals Inc.’s holdings in Pfizer were worth $530,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Mather Group LLC. increased its position in Pfizer by 35.0% during the third quarter. Mather Group LLC. now owns 34,169 shares of the biopharmaceutical company’s stock worth $1,133,000 after purchasing an additional 8,857 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Pfizer by 97.8% during the third quarter. Tower Research Capital LLC TRC now owns 183,802 shares of the biopharmaceutical company’s stock worth $6,097,000 after purchasing an additional 90,896 shares during the last quarter. Cape Cod Five Cents Savings Bank increased its position in Pfizer by 103.6% during the third quarter. Cape Cod Five Cents Savings Bank now owns 57,884 shares of the biopharmaceutical company’s stock worth $1,920,000 after purchasing an additional 29,459 shares during the last quarter. Teza Capital Management LLC acquired a new stake in Pfizer during the third quarter worth about $347,000. Finally, Ironwood Investment Counsel LLC increased its position in Pfizer by 4.9% during the third quarter. Ironwood Investment Counsel LLC now owns 40,639 shares of the biopharmaceutical company’s stock worth $1,348,000 after purchasing an additional 1,913 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.7 %

NYSE PFE opened at $27.99 on Friday. The firm has a 50 day simple moving average of $27.90 and a 200-day simple moving average of $27.69. The firm has a market cap of $158.61 billion, a price-to-earnings ratio of -466.42, a PEG ratio of 1.09 and a beta of 0.70. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the previous year, the company posted $1.23 EPS. The company’s quarterly revenue was down 19.5% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PFE. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.